Novo Nordisk Heads to New Orleans with a Cleaner Competitive Field and a Pipeline to Prove

The stars are aligning for Novo Nordisk, but the market is still waiting for the fireworks. A regulatory clampdown on cheap copycat GLP-1s is clearing the competitive landscape just as the Danish pharma giant prepares to unveil a heavy data package at the American Diabetes Association’s annual meeting. For a stock that has shed roughly 36% over the past twelve months and sits more than 44% below its 52-week peak, the convergence of these two catalysts could be decisive.

The biggest near-term relief comes from Washington. The FDA has circulated a draft rule that would all but end the mass production of compounded GLP-1 analogues by so-called 503A and 503B pharmacies. These imitations had at one point captured nearly 30% of market volume by exploiting shortages of the branded originals. Jefferies now estimates that share has already slipped to around 15% — and expects a full implementation of the new restrictions by mid-2027. For Novo Nordisk, that means the pricing pressure from “copycat” operators is fading faster than many had anticipated.

Jefferies analyst Michael Leuchten nevertheless remains cautious. In a note published on Friday, he affirmed a “Hold” rating and a target price of 270 Danish kroner, roughly 10% below the current level. The stock traded at about 38.90 euros on Monday, just under its 100-day moving average, having recovered about 27% from its March trough. The RSI of 48 points to neutral sentiment — neither oversold nor overheated.

The company’s pipeline progress is starting to deliver tangible revenue. Oral semaglutide — the pill version of Wegovy — secured a positive EU approval recommendation in May. In its first full quarter on the US market, the oral formulation generated around 2.3 billion Danish kroner in sales, comfortably beating analyst expectations. A high-dose injectable Wegovy is also nearing regulatory submission. But the competitive clock is ticking: Eli Lilly’s oral GLP-1, Foundayo, has been on the US market since April 2026.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

The real firepower will be on display in New Orleans from June 5 to 8. Novo Nordisk is scheduled to present a total of 40 abstracts at the ADA Scientific Sessions. The centerpiece is the Phase 3 REIMAGINE programme for CagriSema — a combination of the amylin analogue cagrilintide and semaglutide — with data on blood-glucose control and weight loss in type 2 diabetes patients on various background therapies. A dedicated symposium is set for June 7.

On the same day, the company will host an R&D investor day to discuss the results in detail. That gives the date a dual significance: clinical evidence and capital-markets communication rolled into one. Also on the agenda are Phase 2b results for zenagamtide (formerly Amycretin), a single-molecule GLP-1/amylin agonist being developed in both oral and subcutaneous formulations. Neither candidate has yet been approved in the US.

Beyond the headline candidates, the 40 abstracts cover semaglutide in cardiovascular, renal and pulmonary indications — including asthma, sleep apnoea and MASH — as well as data on the once-weekly insulins Icodec and IcoSema. The broader message is that Novo Nordisk’s GLP-1 franchise extends far beyond weight loss, a crucial narrative given the intensifying pricing headwinds in its home market. In the first quarter of 2026, adjusted US sales fell 11% on a comparable-currency basis.

Novo Nordisk at a turning point? This analysis reveals what investors need to know now.

For investors, the stakes are clear: the CagriSema and zenagamtide data must deliver the clinical conviction the stock has been lacking. If the results are compelling, the stock has room to climb toward its 200-day moving average of roughly 42 euros. If they disappoint, the recovery from the March lows will prove short-lived. The numbers land on the table from June 5 — and the market will not be patient.

Ad

Novo Nordisk Stock: New Analysis - 29 May

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69444829 |